

**Snell & Wilmer L.L.P.**  
600 Anton Boulevard  
Suite 1400  
Costa Mesa, California 92626-7689  
TELEPHONE: (714) 427-7000  
FACSIMILE: (714) 427-7799

April 12, 2010

**Via EDGAR**

Division of Corporation Finance  
Securities and Exchange Commission  
100 F. Street, N.E.  
Washington, D.C. 20549-7010  
Mail Stop 4720  
Attn.: Jim B. Rosenberg, Senior Assistant Chief Accountant

**RE: Peregrine Pharmaceuticals, Inc.  
Form 10-K for the Year Ended April 30, 2009  
Filed on July 14, 2009  
File No.: 001-32839**

Dear Mr. Rosenberg:

Our client, Peregrine Pharmaceuticals, Inc. (the "Company"), is in receipt of the Staff of the Securities and Exchange Commission's (the "Commission") letter dated March 29, 2010 to Paul J. Lytle, Chief Financial Officer of the Company, with respect to the Company's Form 10-K for the year ended April 30, 2009. The purpose of this letter is to advise you that the Company is working on the response to the Commission's letter and anticipates filing such response on or before Wednesday, April 14, 2010.

If you have any questions, please do not hesitate to give me a call at (714) 427-7402.

Very truly yours,

Snell & Wilmer

/s/ Mark R. Ziebell  
Mark R. Ziebell

cc: Paul J. Lytle